TIL · Instil Bio, Inc. - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Revenue | - | - | - | - | $138.0K |
| Cost of Revenue | - | - | - | - | - |
| Gross Profit | - | - | - | - | - |
| R&D | $24.74M | $11.84M | $39.60M | $141.06M | $19.40M |
| SG&A | $27.22M | $44.21M | $47.55M | $62.23M | $14.38M |
| Total Operating Expenses | $78.58M | $73.54M | $159.17M | $226.46M | $33.78M |
| D&A | $534.0K | $3.61M | $4.76M | $5.99M | $256.0K |
| Operating Income | ($78.58M) | ($73.54M) | ($159.17M) | ($226.46M) | ($33.64M) |
| Interest Expense | $5.83M | $8.99M | $5.21M | $0 | - |
| Income Tax | $0 | - | $0 | ($2.07M) | $151.0K |
| Net Income | ($71.37M) | ($74.14M) | ($156.09M) | ($223.18M) | ($37.74M) |
| EPS - Basic | ($10.70) | ($11.39) | ($24.00) | ($34.40) | ($47.20) |
| EPS - Diluted | ($10.70) | ($11.39) | ($24.00) | ($34.40) | ($47.20) |
Balance Sheet
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Cash & Equivalents | $6.64M | $8.80M | $9.20M | $43.72M | $37.59M |
| Accounts Receivable | - | - | - | - | - |
| Inventory | - | - | - | - | - |
| Accounts Payable | $779.0K | $659.0K | $1.21M | $2.36M | $5.57M |
| Current Assets | $191.43M | $124.47M | $160.76M | $269.38M | $464.02M |
| Total Assets | $203.52M | $263.57M | $325.63M | $482.13M | $609.98M |
| Current Liabilities | $4.84M | $7.90M | $10.56M | $32.79M | $41.36M |
| Long-term Debt | - | - | - | - | - |
| Total Liabilities | $89.66M | $94.13M | $99.80M | $118.52M | $54.78M |
| Stockholders' Equity | $113.87M | $169.44M | $225.83M | $363.61M | $555.20M |
| Retained Earnings | ($726.49M) | ($655.12M) | ($580.98M) | ($424.89M) | ($201.72M) |
Cash Flow
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Operating Cash Flow | ($36.62M) | ($55.70M) | ($82.03M) | ($180.16M) | ($29.62M) |
| Investing Cash Flow | $25.48M | $53.97M | $41.13M | $114.54M | ($51.12M) |
| Financing Cash Flow | $7.29M | $1.75M | $8.08M | $71.89M | $313.05M |
| CapEx | - | $0 | $20.66M | $84.59M | $50.82M |
| Free Cash Flow | - | ($55.70M) | ($102.69M) | ($264.75M) | ($80.43M) |
Ratios
| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Profitability | |||||
| Gross margin | - | - | - | - | - |
| Operating margin | - | - | - | - | -24379.7% |
| EBITDA margin | - | - | - | - | -24194.2% |
| Net margin | - | - | - | - | -27346.4% |
| Free cash flow margin | - | - | - | - | -58284.1% |
| FCF / Net income | - | 0.75 | 0.66 | 1.19 | 2.13 |
| R&D / Revenue | - | - | - | - | 14057.2% |
| SG&A / Revenue | - | - | - | - | 10422.5% |
| Effective tax rate | - | - | - | - | - |
| Return on assets | -35.1% | -28.1% | -47.9% | -46.3% | -6.2% |
| Return on equity | -62.7% | -43.8% | -69.1% | -61.4% | -6.8% |
| Return on invested capital | - | - | - | - | - |
| Liquidity | |||||
| Current ratio | 39.53 | 15.76 | 15.22 | 8.22 | 11.22 |
| Quick ratio | 39.53 | 15.76 | 15.22 | 8.22 | 11.22 |
| Cash ratio | 1.37 | 1.12 | 0.87 | 1.33 | 0.91 |
| Leverage | |||||
| Debt / Equity | - | - | - | - | - |
| Debt / Assets | - | - | - | - | - |
| Debt / EBITDA | - | - | - | - | - |
| Interest coverage | -13.5x | -8.2x | -30.6x | - | - |
| Equity multiplier | 1.79 | 1.56 | 1.44 | 1.33 | 1.10 |
| Liabilities / Assets | 0.44 | 0.36 | 0.31 | 0.25 | 0.09 |
| Efficiency | |||||
| Asset turnover | - | - | - | - | 0.00 |
| Inventory turnover | - | - | - | - | - |
| Days sales outstanding | - | - | - | - | - |
| Days inventory outstanding | - | - | - | - | - |
| Days payable outstanding | - | - | - | - | - |
| Cash conversion cycle | - | - | - | - | - |
| Valuation | |||||
| P / E | - | - | - | - | - |
| P / B | 0.6x | 0.7x | 0.2x | 4.5x | 9.9x |
| P / S | - | - | - | - | 39669.9x |
| EV / EBITDA | - | - | - | - | - |
| Growth | |||||
| Revenue growth (YoY) | - | - | - | - | - |
| Revenue CAGR (3y) | - | - | - | - | - |
| Revenue CAGR (5y) | - | - | - | - | - |
| Gross profit growth (YoY) | - | - | - | - | - |
| Operating income growth (YoY) | -6.9% | 53.8% | 29.7% | -573.1% | - |
| Net income growth (YoY) | 3.7% | 52.5% | 30.1% | -491.4% | - |
| EPS growth (YoY) | 6.1% | 52.5% | 30.2% | 27.1% | - |
| EPS CAGR (3y) | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - |
| FCF growth (YoY) | - | 45.8% | 61.2% | -229.2% | - |
| FCF CAGR (5y) | - | - | - | - | - |
| Book value growth (YoY) | -32.8% | -25.0% | -37.9% | -34.5% | - |
Stability scores
Piotroski F-score
FY 2025 · 9-point quality
2/9
Weak
- ✗Net income positive
- ✗Operating cash flow positive
- ✗ROA improved YoY
- ✓Cash flow > net income
- -Long-term debt decreased
- ✓Current ratio improved
- ✗No share dilution
- -Gross margin improved
- -Asset turnover improved
Peer comparison
Same SIC group: Biological Products, (No Diagnostic Substances)
Comparing Instil Bio against the 5 most active filers in the same SIC group.